Actinogen Medical Limited
ATGGF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $5 | $0 | $9 | $1 |
| % Growth | – | -100% | 892.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $5 | $0 | $9 | $1 |
| % Margin | 100% | – | 100% | 76.7% |
| R&D Expenses | $8 | $5 | $7 | $9 |
| G&A Expenses | $1 | $1 | $1 | $1 |
| SG&A Expenses | $5 | $4 | $4 | $3 |
| Sales & Mktg Exp. | $3 | $3 | $3 | $2 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $12 | $8 | $10 | $12 |
| Operating Income | -$7 | -$8 | -$1 | -$11 |
| % Margin | -123.4% | – | -15.5% | -1,258.6% |
| Other Income/Exp. Net | $0 | -$0 | -$9 | -$1 |
| Pre-Tax Income | -$7 | -$8 | -$11 | -$12 |
| Tax Expense | $0 | $0 | -$9 | -$1 |
| Net Income | -$7 | -$8 | -$1 | -$12 |
| % Margin | -119.6% | – | -16.5% | -1,271.3% |
| EPS | -0.002 | -0.28 | -0.001 | -0.005 |
| % Growth | 99.2% | -39,900% | 85.7% | – |
| EPS Diluted | -0.002 | -0.28 | -0.001 | -0.005 |
| Weighted Avg Shares Out | 3,043 | 29 | 2,285 | 2,339 |
| Weighted Avg Shares Out Dil | 3,042 | 29 | 2,285 | 2,339 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$7 | -$8 | -$1 | -$12 |
| % Margin | -124.1% | – | -16% | -1,346.8% |